Skip to main content
Ravomialisoa Razafimanantsoa on Muck Rack

Ravomialisoa Razafimanantsoa

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ravomialisoa

Contact Ravomialisoa, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Schistosomiasis vaccine SchistoShield® induces functional immune memory responses in US and African populations

|
By Mumtaz Balkhi, Desalegn W. Kifle, Mohamadou Siribié, Asma Binte Aziz, Birkneh T. Tadesse, Amidou Diarra, Sean Gray, Rhea N. Coler, Jinhee Lee, Raphaël Rakotozandrindrainy, Sodiomon B Sirima, Lisa Jackson, Florian Marks, Darrick Carter, Afzal Siddiqui, Aravindan Kalyanasundaram, Aryandra Arya, Mallory Mckinnon, Dinesh Krishnappa, Harshvardhan Shrivastava, Hyonjin Jeon, Tanyada Yongchaitrakul, Njariharinjakamampionona Rakotozandrindrainy, Ravomialisoa Razafimanantsoa, Henry Bere Noellie, Nebié Issa Ouedraogo
| Nature Verified
Abstract Helminth parasites of the genus Schistosoma cause 290,000 deaths annually, mostly in tropical and subtropical regions. An estimated 250 million people are currently chronically infected with Schistosoma parasites, imposing a risk of new and recurrent infections in an additional 800 million people. SchistoShield® (Sm-p80 + GLA-SE) is a leading vaccine candidate for schistosomiasis that has successfully completed Phase 1 (USA) and Phase 1b (Africa) safety and immunogenicity clinical trials.
Open in Who Shared Issue with article?
See all 1 articles